GOODWILL AND INTANGIBLE ASSETS

9 Months Ended

Apr. 30, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

The following table presents goodwill, allocated by reportable segment.



	Apr 30, 2013		Jul 31, 2012
Life Sciences	$	180,531	$	178,359
Industrial	161,646		160,582
	$	342,177	$	338,941

Intangible assets, net, consist of the following:



	Apr 30, 2013
	Gross		Accumulated Amortization		Net
Patents and unpatented technology	$	126,219	$	70,712	$	55,507
Customer-related intangibles	97,107		20,614		76,493
Trademarks	13,275		5,982		7,293
Other	4,457		2,592		1,865
	$	241,058	$	99,900	$	141,158

	Jul 31, 2012
	Gross		Accumulated Amortization		Net
Patents and unpatented technology	$	125,938	$	65,262	$	60,676
Customer-related intangibles	93,901		13,323		80,578
Trademarks	13,104		5,269		7,835
Other	5,179		3,124		2,055
	$	238,122	$	86,978	$	151,144

Goodwill and intangible assets were primarily impacted by changes in the foreign exchange rates used to translate goodwill and intangible assets of foreign subsidiaries. Intangible assets were additionally impacted by the acquisition of a distributor in the third quarter of fiscal year 2013.

Amortization expense from continuing operations for intangible assets for the three and nine months ended April 30, 2013 was $4,765 and $14,900, respectively. Amortization expense from continuing operations for intangible assets for the three and nine months ended April 30, 2012 was $5,911 and $14,610, respectively (excluded is amortization expense included in discontinued operations for the three and nine months ended April 30, 2012 of $45 and $136, respectively). Amortization expense is estimated to be approximately $4,655 for the remainder of fiscal year 2013, $17,987 in fiscal year 2014, $16,114 in fiscal year 2015, $14,866 in fiscal year 2016, $14,787 in fiscal year 2017 and $14,639 in fiscal year 2018.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References+ Details